USCOM LIMITED — Investor Presentation 2020

Jul 13, 2020

Prof. Rob Phillips

PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia

==> picture [360 x 540] intentionally omitted <==

----- Start of picture text -----

July 14 [th] 2020
----- End of picture text -----

==> picture [95 x 23] intentionally omitted <==

“

Uscom delivers record growth in a rapidly shrinking commercial world.

Medical technology is a cornerstone of health and investment, and Uscom continues to execute a targeted global strategy of growth and expansion. While the future is uncertain, China, Uscom’s major market, is rebounding, as Uscom is expanding into Europe and the US.

Uscom has life saving devices in all the major global markets and a product pipeline to ensure revenue growth foreseeably.

Uscom is becoming a global, vertically integrated Medical Technology leader. ” Prof. Rob Phillips

==> picture [409 x 273] intentionally omitted <==

==> picture [48 x 57] intentionally omitted <==

THE USCOM MISSION

==> picture [78 x 79] intentionally omitted <==

Ambitious and growth driven

Uscom – The Measure of Life

RAP©

RESULTS – RECORD YEAR

==> picture [130 x 115] intentionally omitted <==

1. Record annual cash receipts $4.6M (up 36%), revenue and sales 2. Record annual net cash flow up $2.07M and debt free 3. Record H2 – First profitable and cash flow positive half 4. Record H2 – Cash receipts $3.02M (up 84%), Sales $2.87 (up 64%)

5. Record H2 receipts, revenue and sales approx. = full FY19 results 6. Record Q4 – Cash receipts ($1M) 7. Record Q4 – Sales ($0.87M)

Uscom – The Measure of Life

==> picture [48 x 57] intentionally omitted <==

RAP©

==> picture [306 x 540] intentionally omitted <==

UCM Cash Receipts

==> picture [281 x 325] intentionally omitted <==

----- Start of picture text -----

$5.00
$4.60
↑ 36%
$4.00
$3.50
$3.39
$2.94 $2.90
$3.00
$2.04
$2.00
$1.38
$1.01
$1.00 $0.86
$0.00
2012 2013 2014 2015 2016 2017 2018 2019 2020
$M AUD
----- End of picture text -----

==> picture [37 x 37] intentionally omitted <==

ASX:UCM

➢ Record Cash Receipts and Sales

➢ Growth Trend Continues

➢ Cash Receipts $4.6M up 36%

➢ H2 Profitable

➢ Cash on Hand

➢ Debt Free

==> picture [48 x 57] intentionally omitted <==

==> picture [306 x 540] intentionally omitted <==

UCM Annual Results

==> picture [316 x 339] intentionally omitted <==

----- Start of picture text -----

↑ 36%
5.00
4.6
↑ 29%
4.00
3.65
3.39
3.00 2.84
2.00
↑ $2.07M FY 19
FY 20
1.00 0.78
↑ $0.04M
0.00
Profit Net Cash Sales Cash
Flow Receipts
-1.00
-1.29
-1.4-1.36
-2.00
$M AUD
----- End of picture text -----

==> picture [37 x 37] intentionally omitted <==

ASX:UCM

• ➢ Record results

• ➢ Cash receipts $4.6M up 36%

• ➢ Sales $3.65M up 29%

• ➢ Net cash flow up $2.07M

• ➢ Poor H1 due to global restructure, with record H2

• ➢ Cash on hand

• ➢ Debt free

==> picture [48 x 57] intentionally omitted <==

==> picture [306 x 540] intentionally omitted <==

UCM H2

==> picture [317 x 328] intentionally omitted <==

----- Start of picture text -----

3.50 ↑ 84%
↑ 62%
3.02
3.00 2.87
2.50
2.00
1.78
1.64
1.50
↑ $1.47M
2019
1.00
↑ $0.78M 2020
0.50
0.50
0.14
0.00
Profit Net Cash Sales Cash
Flow Revenue Receipts
-0.50
-0.64
-1.00
-0.97
-1.50
$M AUD
----- End of picture text -----

==> picture [37 x 37] intentionally omitted <==

ASX:UCM

• ➢ Record H2 Results

• ➢ Cash receipts $3.02M up 84%

• ➢ Sales revenue $2.87M up 62%

• ➢ Net cash flow up $1.47M

• ➢ Profit up $0.78M

• ➢ Profitable, cash flow positive

• and record cash receipts

• ➢ Receipts, revenue and cash flow equal to full year 2019

==> picture [48 x 57] intentionally omitted <==

==> picture [306 x 540] intentionally omitted <==

==> picture [344 x 386] intentionally omitted <==

----- Start of picture text -----

UCM 4C Q4 ↑ 57%
2.00 1.92
↑27%
1.50
1.21
↑ $0.06M
1.00
1.00
0.87
0.81 0.79
FY 19
0.50
FY 20
↑ $0.10M
0.00
Net Cash Sales Cash Cash on
Flow Revenue Receipts Hand
-0.35
-0.50
-0.45
-1.00
$M AUD
----- End of picture text -----

==> picture [37 x 37] intentionally omitted <==

ASX:UCM

➢ Record Q4 results

➢ Cash receipts $1.00M up 27%

➢ Sales revenue $0.87M up 7%

➢ Net Cash flow up $0.10M

➢ Cash on hand up 57%

➢ $400K FX loss and inventory

==> picture [48 x 57] intentionally omitted <==

INNOVATION

Uscom technology provides the highest quality personal spirometers allowing home lung function testing at research standards.

==> picture [314 x 411] intentionally omitted <==

Uscom Digital Spirometry

Ultrasonic Flow Technology

“FOR MEDICAL TECHNOLOGY COMPANIES INNOVATION DETERMINES FUTURE REVENUE USCOM CONTINUES TO DEVELOP NEW DEVICES AND IMPROVES CURRENT TECHNOLOGIES”

==> picture [40 x 164] intentionally omitted <==

==> picture [18 x 19] intentionally omitted <==

==> picture [19 x 19] intentionally omitted <==

==> picture [19 x 19] intentionally omitted <==

==> picture [19 x 19] intentionally omitted <==

==> picture [19 x 19] intentionally omitted <==

==> picture [48 x 58] intentionally omitted <==

The / Measure / of / Life

==> picture [278 x 67] intentionally omitted <==

==> picture [308 x 367] intentionally omitted <==

==> picture [156 x 20] intentionally omitted <==

==> picture [444 x 515] intentionally omitted <==

NEW PRODUCT - VENTITEST

==> picture [216 x 53] intentionally omitted <==

VentiTest is a multi-path ultrasonic ventilator test device with PC based display and analytics designed for pressure, flow and volume testing and calibration of ventilator outputs.

Uscom is increasing manufacture and marketing of VENTITEST Hospital Departments need 1 VentiTest per 10 ventilators, Estimated 10,000 unit sales = $25M revenue

✓ Unique Technology

Based on multi-path digital ultrasound

==> picture [25 x 25] intentionally omitted <==

==> picture [22 x 21] intentionally omitted <==

==> picture [19 x 20] intentionally omitted <==

==> picture [19 x 19] intentionally omitted <==

==> picture [19 x 19] intentionally omitted <==

✓ High Market Interest

Exploding demand for COVID-19 ventilators worldwide Around 1M ventilators all require regular calibration

==> picture [48 x 57] intentionally omitted <==

The / Measure / of / Life

GROWING GLOBAL

==> picture [148 x 89] intentionally omitted <==

• London • Beijing • Budapest • LA Operations Sydney Beijing • Singapore Budapest Offices Singapore Auckland • Sydney • Auckland London LA

Multiple products hedged for currencies and markets

RAP©

==> picture [38 x 39] intentionally omitted <==

2021 GROWTH DRIVERS

==> picture [275 x 35] intentionally omitted <==

==> picture [179 x 70] intentionally omitted <==

==> picture [151 x 60] intentionally omitted <==

==> picture [42 x 40] intentionally omitted <==

VENTITEST – Uscom ventilator calibration

BP+ and SpiroSonic approvals due for China and US

Europe and US up-grading and increasing infectious disease centres

New European and US distribution models

Uscom China growing - numbers and quality of distributors

China economy rebounding – boom market

==> picture [54 x 65] intentionally omitted <==

2021 Risks

==> picture [670 x 326] intentionally omitted <==

----- Start of picture text -----

Regulatory Travel limitation
approvals become impairs global
trade protection management
Compliance
Global disorder and
overload – cost,
slow economic
intervention and
recovery
inefficiency
----- End of picture text -----

==> picture [156 x 20] intentionally omitted <==

==> picture [43 x 42] intentionally omitted <==

==> picture [48 x 57] intentionally omitted <==

UCM – TIGHTLY HELD

==> picture [275 x 35] intentionally omitted <==

Quality growth stock Invested management Strong strategic vision Record growth in fundamentals

~150M FPO UCM shares on issue ~35±10c (Current price 22c) ~$35M Cap Value Top 20 own 68% CEO and NED own ~20% each China Director and Distributor owns ~1.5% each

==> picture [139 x 105] intentionally omitted <==

Shareholding

==> picture [433 x 288] intentionally omitted <==

----- Start of picture text -----

NED
CEO
Ex CEO
Investor 1
Free Float
Investor 2a
31%
Investor 2b
Investor 3
Distributor
Investor 4
China Director
Investor 5
11 to 20
Free Float
----- End of picture text -----

UCM is tightly held by experienced investors

==> picture [48 x 57] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

==> picture [36 x 37] intentionally omitted <==

RESULTS

01

02

03

04

05

06

Record Cash Receipts

$4.6M up 36% with cash on hand

China Strong and Rebounding

Expanding operations and recovering activity and orders

H2 – Profitable cash flow positive, debt free

Europe Expanding sales activity increasing

New Product - VentiTest for market in second half

==> picture [48 x 57] intentionally omitted <==

Invested in the Future Products and operations

CONCLUSION

“

2020 was a year of record financial results with profit and cash flow positivity and rapid growth in the second half following global restructure and Uscom China establishment.

Investment in China and all major markets is planned to deliver continuing growth with new products to drive future revenues.

Uscom is establishing a company of global clinical, social and commercial importance and significant investor value.

”

Prof. Rob Phillips CEO

==> picture [38 x 46] intentionally omitted <==

Prof. Rob Phillips

PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Chairman, CEO, Chief Scientist, Uscom Limited, Sydney, Australia Critical Care Research Group, School of Medicine, The University of Queensland, Brisbane, Australia

==> picture [360 x 540] intentionally omitted <==

----- Start of picture text -----

July 14 [th] 2020
----- End of picture text -----

Corporate Social Responsibility

==> picture [68 x 82] intentionally omitted <==

Winning the battle against Cape York’s feral pigs